Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Osimertinib (Tagrisso) for locally advanced or metastatic non-small cell lung cancer, EGFR mutation positive (Ex19del or L858R) - first line	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation	Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications